

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS-Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 28, 2004 Signature: Shawn P. Foley
(Shawn P. Foley)

Docket No.:
FELDER 3.9-001 CONT DIV
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Felder et al.

Application No.: 10/677,983

Confirmation No.:

Filed: October 2, 2003

Art Unit: 1645

For: G PROTEIN-RELATED KINASE MUTANTS
IN ESSENTIAL HYPERTENSION

Examiner: Not Yet
Assigned

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, dated October 28, 2004.
(copy enclosed)

In order to comply with the requirements directed to sequence listings, applicants hereby make reference to their parent Application No. 09/614,748, filed July 12, 2000, now United States Patent Number 6,660,474, in which a Sequence Listing (in both paper and computer readable forms) was submitted. It was found to be compliant with all relevant rules. Accordingly, applicants hereby request the use of the compliant sequence listing filed in said parent application in this patent application. See 37 C.F.R. § 1.821(e).


To comply with the Notice, however, Applicants enclose a paper copy of the Sequence Listing which is identical to the computer readable form in the parent application under Rule 1.821(e), and a Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§ 1-821-1.825. Further, enclosed is a courtesy copy of the Sequence Listing in computer readable form and a Preliminary Amendment directing incorporation of the paper copy of the Sequence Listing into the specification.

The Examiner is encouraged to contact the undersigned if there are any questions concerning this correspondence, he or she is requested to call applicant's attorney at (908) 654-5000. If any additional fees are required by the present Communication, the Examiner is hereby authorized to charge them to our Deposit Account No. 12-1095.

Dated: December 28, 2004

Respectfully submitted,

By Shawn P. Foley
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

JRW
BW
Sey

| APPLICATION NUMBER | FILING OR 371 (c) DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|------------------------|-----------------------|-------------------------|
| 10/677,983 | 10/02/2003 | Robin A. Felder | FELDER 3.9-001 CONT DIV |

000530
 LERNER, DAVID, LITTENBERG,
 KRUMHOLZ & MENTLIK
 600 SOUTH AVENUE WEST
 WESTFIELD, NJ 07090

CONFIRMATION NO. 9056

FORMALITIES LETTER



OC000000014232003

Date Mailed: 10/28/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>
- For Patentin Software Program Help, call (571) 272-2510 or email mark.spencer@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450
 Alexandria VA 22313-1450

Glide N.
*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE